Introduction
Acinetobacter baumannii is a glucose nonfermentative, Gram-negative bacillus classified as a significant opportunistic pathogen and is usually involved in infectious outbreaks originating in intensive care units (1) . The infections caused by A. baumannii include bacteremia, ventilator-associated pneumonia, meningitis, urinary tract and wound infections (2) . The number of multidrug resistant (MDR) strains of A. baumannii has increased in recent years and therefore treatment of this organism is complicated (3) . The terms of pan drug resistance (PDR), extensive drug resistance (XDR) and multidrug resistance (MDR) were explained as, resistance of an isolate to all antibiotics in all antimicrobial categories, resistance to at least one antibiotic in all expect one or two antimicrobial categories and resistance to at least one antibiotic in ≥3 antimicrobial categories, respectively.
The antimicrobial categories were included aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillins, monobactams and polymyxins (4) .
Carbapenems are considered a last-line agent for the treatment of important Gram-negative bacilli, but resistance to these compounds in A. baumannii has been increased worldwide within the past decade (5, 6) . Several mechanisms involved in resistance to carbapenem antibiotics in A. baumannii among them OXA-type beta-lactamases are the most widespread mechanism (7) . At the present five main groups of OXA-type beta-lactamases have been identified in A. baumannii: blaOXA-23-like; blaOXA-40-like; blaOXA-51-like; blaOXA-58-like and blaOXA-143-like (8, 9) . The OXA-type betalactamases contain between 243 and 260 amino acids residues, with a molecular mass ranging from 23 to 35.5 kDa (10). The first report of OXA-type betalactamases in A. baumannii was from Scotland in 1985 that named ARI-1 (Acinetobacter Resistant to Imipenem) (11) and later designated as OXA-23 (12) . Nowadays, this gene has been discovered from many countries of the world (13) . The second group of OXAtype beta-lactamases is blaOXA-40-like, originally called OXA-24, which was initially found in A. baumannii from Spain (14) . This gene encoded chromosomally or by plasmid and has 60% identity with OXA-23 (1) . The largest group of OXA-type beta-lactamases is the blaOXA-51-like, which corresponds to chromosomal encoded enzymes and therefore naturally occurs in A. baumannii (15) . The fourth group is blaOXA-58-like that was identified in France (16) . These enzymes often located on plasmids, which may explain their wide distribution (1) . Recently, Higgins et al. reported a new OXA-type beta-lactamase, the OXA-143, which isolated from a carbapenem resistant A. baumannii in Brazil. This gene has been identified in plasmid and so far was not reported from other countries of the world (8) . The purpose of this study was to access the antibiotic susceptibility profile and the rate of MDR, XDR and PDR A. baumannii isolated from different hospitals in Qom in center of Iran and to investigate the distribution of OXA-type beta-lactamases among A. baumannii.
Materials and Methods

Bacterial isolation and identification
A total of l08 non-duplicate isolates of A. baumannii were collected from clinical specimens of hospitalized patients in (four teaching hospitals in Qom, Iran) Shahid-beheshti hospital (a 530-bed referral hospital with three 12-bed ICUs), Nekoei Hospital (a 170-bed referral hospital), Kamkar Hospital (a 150-bed referral hospital) and Valiasr Hospital (a 158-bed referral hospital) between November 2012 and October 2013. The isolates were obtained from clinical specimens, including tracheal aspirate, urine, blood, wounds and cerebrospinal fluid. The identification of the isolates was performed using standard microbiological and biochemical tests such as Gram stain, colony morphology, glucose oxidation, citrate utilization, oxidase tests and growth at 44 °C (17) . In addition, identification of A. baumannii was confirmed using blaOXA-51 PCR (18) .
Antibiotic susceptibility testing
Susceptibility to a panel of 18 antimicrobial agents was determined by Kirby-Bauer disc diffusion according to Clinical and Laboratory Standard Institution (CLSI) guideline (19). Antibiotics used were ceftriaxon (30 µg), ceftazidime (30 µg), gentamicin (10 µg), amikacin (30 µg), ciprofloxacin (5 µg), piperacillin (100 µg), piperacillintazobactam (100/10 µg), imipenem (10 µg), meropenem (10 µg), aztreonam (30 µg), cefepime (30 µg), levofloxacin (5 µg), ampicillin-sulbactam (10/10 µg), trimethoprimesulfamethoxazole (25 µg), ticarcillin-clavulanic acid (75/10 µg), tobramycin (10 µg), colistin (10 µg), polymyxin B (30 unit) (MAST, Merseyside, United Kingdom). Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as controls. Intermediate sensitivity was considered as resistance.
DNA extraction and PCR assay
All A. baumannii isolates were grown for 24 hr at 37 °C in MacConkey agar then pure colonies were isolated and cultured in the LB broth medium and DNA was extracted by boiling method (20 
Results
A total of 108 A. baumannii isolates were recovered from clinical specimens collected in four teaching hospitals in Qom, Iran. Clinical samples were tracheal aspirate (81 isolates, 75%), urine (17 isolates, 15.74%), blood (7 isolates, 6.48%), wounds (2 isolates, 1.85 %) and cerebrospinal fluid (1 isolate, 0.93%). The age ranges of the patients were from 20 to 90 years old with a median of 52 years. Seventy-five (69.44%) patients were male and thirty-three (30.56%) were female. A. baumannii isolates were collected from different hospital wards as follows; ICU wards (92 isolates, 85.19%), burn wards (2 isolates, 1.85%), trauma and emergency wards (7 isolates, 6.48%), general surgery wards (2 isolates, 1.85%) and internal wards (5 isolates, 4.63%). Analysis for presence of blaOXA-51-like gene with PCR method showed that all isolates were positive for this gene and confirmed them as A. baumannii. A. baumannii isolates showed 100% resistance to aztreonam and ticarcillin-clavulanic. In addition, 41.6% and 12% of the isolates were resistant to colistin and polymixin B, respectively (Table 1 ). In addition, among 108 A. baumannii isolates screened 12 isolates (11.11%) were multidrug resistant (MDR), 89 isolates (82.4%) were extensive drug resistant (XDR) and 6 isolates (5.55%) were pandrug resistant (PDR). Of the total 108 A. baumannii collected in this study, 97 isolates (89.81%) were found non-susceptible to imipenem and meropenem. (Figure 1 ). The sequencing and alignment results for PCR product of blaOXA-143-like gene was showed that sequence of this gene was 100% similar to sequences of blaOXA-143-like genes recorded in the GenBank and registered in GenBank with accession number KX349208. Table 2 shows the genotypic profiles of OXA-type beta-lactamase genes in carbapenem resistant A. baumannii isolates.
Discussion
Nosocomial infections are an important origin of mortality and morbidity in hospitalized patients. A. baumannii plays a significant role in these infections especially in ICU wards due to its resistance against multiple classes of antibiotics (24) . The finding of this study showed that 85.18% of A. baumannii isolates were recovered from hospitalized patients in ICU wards. This result is in line with previous report about the role of A. baumannii in ICU infections (25, 26). Findings of this study showed that 89.81% of A. baumannii isolates were resistant to imipenem and meropenem. Previous reports from Iran showed the resistant rate to imipenem in 50.7% (25), 52% (27) and 62% (28) of A. baumannii isolates which indicates an increase in the rate of resistance to carbapenems. Results of other studies also show that resistance rate to carbapenems in recent years has been increased (29, 30) . Results of PCR amplification (18) . In addition, we found considerable levels of multiple-resistance to antimicrobials tested in our study. The distribution of XDR and PDR among our isolates was found to be 82.4% and 5.55% which was much lower than the rate of XDR (89%) baumannii isolates have been reported from many countries and this gene has found a worldwide dissemination (33) . In studies conducted by Mak et al. and Zhou et al. 87 .5% and 94% of carbapenem resistant isolates had blaOXA-23-like gene, respectively (34, 21) . In our study, 22.68% of carbapenem non-susceptible A. baumannii isolates had blaOXA-40-like gene. This result is similar to the rate of blaOXA-40-like gene reported from central part of Iran (17.9%) (25), but is considerably higher than the rate of this gene reported from northwest of Iran (1.6%) (28) . The highest prevalence of 
Conclusion
This study showed that the rate of resistance to most of the available antibiotics for treatment of infection caused by A. baumannii was high in the study region. This study also revealed that suceptibility to carbapenems in the population of A. baumannii isolates in Iran reduced and the blaOXA-23-like gene was the most prevalent types of carbapenemase among carbapenem resistant A. baumannii isolates in this area. The rapid identification of carbapenemaseproducing isolates is important and the use of specific methods are necessary to control the further transmission of infection by these organisms.
